

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE IN RESPECT OF EXCLUSIVE DISTRIBUTION OF OCTAPHARMA HUMAN ALBUMIN

This is a voluntary announcement made by Sinco Pharmaceuticals Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to keep its shareholders (the “**Shareholders**”) and potential investors of the Company abreast of the latest business development of the Company.

The board of directors (“**Directors**”) of the Company is pleased to announce that, the Group’s existing business partner Octapharma AG has confirmed that Sichuan Sinco Pharmaceuticals Co., Ltd. (四川興科蓉藥業有限責任公司) (being the wholly-owned subsidiary of the Company) to be the exclusive distributor throughout all of the mainland China, for Octapharma Human Albumin 10g (20%, 50ml) produced at Octapharma’s manufacturing plant in Lingolsheim, France for the term from 1 February 2022 to 31 December 2023, which is a newly added authorization in the business cooperation between the Group and the Octapharma AG.

The Group’s principal business is the marketing, promotion and channel management services for improved human plasma-based pharmaceuticals, antibiotics and other pharmaceuticals focused on therapeutic areas and complementary to human plasma-based product and other fast-growing categories in the mainland China. The Directors believe that, by expanding the pharmaceuticals that the Group sells and/or distributes, the Group’s product base will be diversified, which is conducive to the Group’s business and would positively contribute to the Group’s financial results and potentially enhance Shareholders’ value.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 16 February 2022

As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.